Elizabeth Smyth, MD, on Esophageal/GEJ Cancer: Pembrolizumab or Placebo Plus Concurrent Definitive Chemoradiotherapy

November 02, 2026

Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses data from the phase III KEYNOTE-975 study, which examined definitive chemoradiotherapy with or without pembrolizumab in patients with previously untreated locally advanced unresectable esophageal and gastroesophageal junction (GEJ) cancer. Dr. Smyth was a co-chair of the proffered paper session that featured the abstract (Abstract 2875O). 

Related Content